Clinical trials: Treatment Resistant Major Depressive Disorder
Depression
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
The purpose of the study is to evaluate the efficacy of study drug (BMS-820836) as compared with continued Duloxetine/Escitalopram in the treatment of patients with treatment resistant depression (TRD).
- Trial name
- NCT01369095
- Testing
- Duloxetine, Escitalopram, BMS-820836
- Where
- 93 sites in United States, Argentina and 10 more
- Volunteers
- 976 people
- Sponsor
- Bristol-Myers Squibb
Major Depressive Disorder, Depression
Investigating Predictors of Treatment Response in Treatment-Resistant Depression (TRD) With Interleaved TMS/fMRI
The purpose of this trial is identify biomarkers of response to repetitive transcranial magnetic stimulation (rTMS) in individuals with first episode or treatment resistant depression.
- Trial name
- NCT03642522
- Testing
- repetitive transcranial magnetic stimulation
- Where
- Canada
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Treatment Resistant Depression, Depressive Disorder
A Clinical Evaluation of Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression
This is a randomized, placebo-controlled double-blind cross-over trial evaluating the safety, efficacy, daily functioning, and health-related quality of life of Subcallosal Cingulate Gyrus Deep Brain Stimulation (SCG DBS) for…
- Trial name
- NCT01801319
- Testing
- Libra Deep Brain Stimulation System
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Abbott Medical Devices
Major Depressive Disorder
Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression
Our target population will have been adequately treated with one of three selective serotonin reuptake inhibitors (SSRIs; escitalopram, citalopram, or sertraline) for at least 8-12 weeks and continue to experience symptoms of…
- Trial name
- NCT00608543
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Texas Southwestern Medical Center
Major Depressive Disorder, Treatment Resistant Depression
Antidepressant Effects of Nitrous Oxide
To evaluate the acute and sustained antidepressant effects of nitrous oxide in people with major depressive disorder; and further evaluate these effects by identifying the optimal dose and regimen to guide current practice, and…
- Trial name
- NCT05357040
- Testing
- Nitrous oxide gas for inhalation
- Where
- 2 sites in United States, Australia
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Chicago
Major Depressive Episode, Depression - Major Depressive Disorder
Personalized Ultrasonic Brain Stimulation for Depression (R61)
This study will evaluate a new form of non-invasive brain stimulation for individuals with depression. Personalized low-intensity transcranial focused ultrasound stimulation will be delivered using a range of stimulation…
- Conditions
- Major Depressive Episode, Depression - Major Depressive Disorder, Treatment-Resistant Major Depressive Disorder
- Trial name
- NCT06902298
- Testing
- LTFUS to SCC, LTFUS to ALIC
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Brian Mickey
Major Depressive Disorder
Vagal Nerve Stimulation for Treatment Resistant Major Depression
The purpose of this study is to 1) explore whether vagal nerve stimulation (nVNS) using a hand- held non-invasive device (gammaCore™) works to treat depression and 2) to confirm gammaCore™'s safety profile.
- Trial name
- NCT04990687
- Testing
- gammaCore™
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Alabama at Birmingham
Depression, Treatment Resistant Depression
Mindfulness Engaged Neurostimulation for Depression (MEND II)
Repetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region.
- Conditions
- Depression, Treatment Resistant Depression, Major Depressive Disorder, Depressive Disorder
- Trial name
- NCT07512284
- Testing
- Medi-TBS
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of California, San Diego
Treatment Resistant Depression, Major Depressive Disorder
ECT vs. Esketamine
Treatment-resistant depression (TRD) is a common cause of disability and one of the most common psychiatric disorders worldwide. Electroconvulsive therapy (ECT) is currently the most effective treatment for TRD.
- Trial name
- ETES (NCT04924257)
- Testing
- Esketamine nasal spray, Electroconvulsive therapy
- Where
- Austria
- Sponsor
- Medical University Innsbruck
Major Depressive Disorder, Treatment Resistant Depression
Maintenance rTMS for Depression (Maitr-De)
Repetitive transcranial magnetic stimulation (rTMS) has emerged as a promising intervention for treatment-resistant depression (TRD), yet substantial uncertainties persist regarding its efficacy as a maintenance treatment.
- Trial name
- Maitr-De (NCT06938841)
- Testing
- Transcranial Magnetic Stimulation (TMS) - Standard maintenance rTMS:, Transcranial Magnetic Stimulation (TMS) - Clustered maintenance rTMS:
- Where
- 3 sites in United States, Australia
- Volunteers
- 75 people
- Sponsor
- University of California, San Diego
Treatment-resistant Depression
Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression
The study aims to investigate the safety and efficacy of oral psilocybin administered under supportive conditions in treatment-resistant major depression (TRD).
- Trial name
- EPIsoDE (NCT04670081)
- Testing
- Psilocybin, Nicotinamide
- Where
- 2 sites in Germany
- Volunteers
- 144 people
- Sponsor
- Central Institute of Mental Health, Mannheim
Depressive Disorder, Major
A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment
The primary purpose of this study is to assess the long-term safety and tolerability of esketamine nasal spray in combination with a selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI)…
- Trial name
- ESCAPE-LTE (NCT04829318)
- Testing
- Esketamine, SSRI/SNRI
- Where
- 59 sites in Argentina, Belgium and 12 more
- Volunteers
- 183 people
- Sponsor
- Janssen-Cilag Ltd.
Depressive Disorder, Treatment-Resistant
Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine
The overarching aim of this research is to determine the acute effects of ketamine on brain glutamate, functional connectivity and cerebral blood flow in treatment-resistant depression, explore whether the effects are attenuated…
- Trial name
- GO-MARK (NCT04977674)
- Testing
- Naltrexone, Ketamine
- Where
- United Kingdom
- Volunteers
- 27 people
- Sponsor
- King's College London
Late Life Treatment Resistant Depression, Depression - Major Depressive Disorder
The BAARD Study : Evaluating a Computerized Approach to Treatment Selection in Older Adults With Treatment Resistant Depression.
The goal of this clinical trial is to test whether a personalized approach to treatment selection improves symptoms in older adults with treatment-resistant depression.
- Conditions
- Late Life Treatment Resistant Depression, Depression - Major Depressive Disorder, Treatment Resistant Depression
- Trial name
- BAARD (NCT07810738)
- Testing
- Aripiprazole Augmentation, Bupropion Augmentation
- Where
- 3 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder
E-field Guided iTBS for Treatment Resistant Depression
The purpose of this study is to establish how personalization of repetitive transcranial magnetic stimulation (rTMS) can change markers of brain activity and improve treatment response.
- Trial name
- NCT05583747
- Testing
- iTBS
- Where
- 2 sites in Canada
- Volunteers
- 110 people
- Sponsor
- Centre for Addiction and Mental Health
Postpartum Depression
Aripiprazole and Resistant Postpartum Depression
Currently there are no controlled data on the management of postpartum depression that fails to respond to adequate antidepressant therapy.
- Trial name
- NCT01386086
- Testing
- aripiprazole
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Major Depressive Disorder
The Antidepressant Advisor (Study 3): fMRI Study to Predict Treatment Response in Patients With Depression
This prospective observational study (ADeSS-Study3) investigates candidate biomarkers prospectively predicting response to antidepressant medications and prognosis in major depressive disorder (MDD).
- Trial name
- ADeSS_S3 (NCT04342299)
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- King's College London
Multiple Sclerosis, Major Depressive Disorder
Acceptability and Feasibility of Transcranial Magnetic Stimulation (TMS) for Depression in Multiple Sclerosis
The goal of this single-arm, observational pilot study is to learn about the safety, feasibility, preliminary efficacy of TMS for the treatment of depression in people with MS.
- Conditions
- Multiple Sclerosis, Major Depressive Disorder, Treatment Resistant Depression
- Trial name
- NCT06329414
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Utah
Treatment Resistant Depression
Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)
This study is looking at the efficacy, durability, safety, and tolerability of multiple single doses of Ketamine vs. active placebo for treating patients with treatment resistant depression who are taking an antidepressant that…
- Trial name
- NCT01920555
- Testing
- Ketamine
- Where
- 6 sites in United States
- Volunteers
- 99 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder
Ketamine infusions resulted in an acute reduction in global depression scores and in severity of suicidal ideation. The investigators therefore plan to investigate the feasibility and efficacy of repeated intravenous…
- Trial name
- NCT01667926
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Massachusetts General Hospital